Key Highlights
- Arunesh Verma joins Fresenius Kabi as President of USA Operations.
- Verma succeeds John Ducker, who retires after 35 years.
- Verma reports to CEO Pierluigi Antonelli.
- Fresenius Kabi focuses on essential medicines and technologies.
- Company strengthens U.S. manufacturing capabilities.
Source: Business Wire
Notable Quotes
- “I am very pleased to welcome Arunesh Verma to our company at a time when we are successfully executing our #Vision2026 transformation in line with #FutureFresenius, strengthening our commercial operations, and bringing online advanced new U.S. manufacturing capabilities – all designed to support U.S. caregivers. At the same time, I want to thank John Ducker for his outstanding leadership and achievement over 35 years. His contributions have shaped our company’s growth and reputation in the U.S. in profound ways.” — Pierluigi Antonelli, CEO at Fresenius Kabi
- “Fresenius Kabi specializes in putting essential medicines and technologies in the hands of people who care for patients – and this is a purpose to which I have devoted my career of more than 22 years.” — Arunesh Verma, President at Fresenius Kabi USA
SoHC's Take
The appointment of Arunesh Verma as the new President of Fresenius Kabi USA marks a significant step in the company’s ongoing transformation under the Vision2026 initiative. Verma’s extensive experience in the pharmaceutical industry, particularly in leadership roles at Cipla and other major companies, positions him well to drive the growth and innovation needed to support U.S. caregivers effectively. As Fresenius Kabi continues to enhance its manufacturing capabilities and expand its product offerings, Verma’s leadership will be crucial in maintaining the company’s reputation for excellence and commitment to patient care.
